The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

Recruitment & Eligibility

Status: Active, not recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Inclusion criteria (recipients): 1. Patients with end-stage renal disease listed for kidney transplantation at UPMC. 2. On chronic hemodialysis or peritoneal dialysis or stage 5 chronic kidney disease (CKD) defined as a glomerular filtration rate < 15 ml/min 3. Age = 18 4. No available living kidney donor 5. Listed for an isolated kidney transplant at UPMC with <60m of accrued transplant waiting time and/or <60m of dialysis time 6. Have panel reactive antibody level of <98% 7. No obvious contraindication to kidney transplant 8. Able to travel to UPMC for routine post-transplant visits and study visits for a minimum of 12 months after transplantation 9. Able to provide informed consent 10. Be willing to use a contraceptive method for a year after transplant Exclusion criteria (recipients): 1. HIV positive 2. HCVAb or HCV RNA positive 3. Presence of behavioral risk factors for contracting HCV other than being on hemodialysis. These behavioral risk factors are current injection drug use, current intranasal illicit drug use, current percutaneous/parenteral exposures in an unregulated setting. 4. Hepatitis B surface antigen positive 5. History of liver cirrhosis 6. Persistently elevated liver transaminases, defined as ALT/AST at least 3 times the upper limit of normal for a minimum of 3 consecutive months 7. History of atrial fibrillation requiring the use of amiodarone over the past 12m 8. Patients with etiology of renal failure with increased risk of causing early graft failure as assessed by the investigator team 9. Receipt of prior organ transplant 10. Waitlisted for a multi-organ transplant 11. Pregnant women 12. Known allergy to sofosbuvir/velpatasvir 13. Any condition, psychiatric or physical, that in the opinion of the investigator would make it unsafe to proceed with transplantation or interfere with the ability of the subject to participate in the study Inclusion criteria (donors): 1. HCV antibody positive 2. HCV NAT negative or positive 3. Kidney donor profile index (KDPI) score <85 Exclusion criteria (donors): 1. Confirmed HIV positive (positive HIV-1 antibody, positive HIV-2 antibody, positive p24 antigen and/or positive HIV NAT) 2. Confirmed HBV positive (positive hepatitis B surface antigen and/or HBV NAT) 3. Known ongoing therapy for HCV

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Adverse Events;HCV free at 1 year

Secondary Outcome Measures

Name	Time	Method
Transmission rate of HCV from HCVAb+/NAT- donors to HCVAb- recipients;Incidence of allograft rejection;Incidence of graft loss;All-cause mortality;Waitlist time after enrollment

Related Trials

PHASE II CLINICAL STUDY ON THE USE OF HCV+ DONORS FOR SOLID ORGAN TRANSPLANTATION.

Phase 1

ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE - ISMETT

Updated 8/21/2023

Occult Hepatitis C virus in the liver-transplanted patients received anti-HCV therapy

RecruitingNot Applicable

Department of Gastroenterology and Hepatology, Nagasaki University Hospital

Updated 10/17/2023

Hepatitis C in renal transplant recipients – Safety and efficacy of a conversion of immunosuppression to high-dose cyclosporine A and its impact on HCV-replication, parameters of liver function and glucose tolerance. An open label trial.

Phase 1

Medizinische Universität Wien

Updated 2/26/2018